Clinical Trials
Clinical trials follow a structured, rigorously controlled process to evaluate the safety and effectiveness of a treatment. They typically consist of multiple phases, beginning with small-scale safety assessments and progressing
Participant Sponsored Observational Study
Table of Contents
Cancer Wellness Clinic of the Pacific is Now Recruiting Immune12 users for our Participant Sponsored study!
The Cancer Wellness Clinic of the Pacific is proud to extend hope to glioblastoma (GBM) patients globally with our innovative product, Immune12. This all-natural therapy is designed to support immune modulation and apoptosis, offering a promising treatment option with zero side effects. Our commitment to holistic cancer care ensures that patients receive the best possible support in their fight against GBM, providing a beacon of hope where the current Standard of Care may fall short.
What are Observational Studies?
Observational studies and clinical trials are both essential components of medical research, but they differ significantly in their design, purpose, and methodology. Below articles describe both components with an example of another observational study.
Virtual Observational Studies
These studies leverage digital platforms to remotely monitor participants in real-world settings. Researchers assess individual responses to Immune12 by collecting data on efficacy, tolerability, quality of life scores and potential
The Salford Lung Studies on COPD
The Salford Lung Studies on COPD demonstrated the value of patient-sponsored observational studies in providing real-world evidence on the effectiveness and safety of new treatments. Participants funded their study and
Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme (GBM) is one of the most aggressive and challenging brain tumors to treat due to:
Tumor Heterogeneity
GBM tumors are highly heterogeneous, meaning they contain a diverse mix of cells with different genetic mutations. This makes it difficult for a single treatment to be effective against all tumor cells.
Glioma Stem Cells
GBM contains stem-like cells that can self-renew and are highly resistant to conventional therapies. These cells can repopulate the tumor even after aggressive treatment.
Blood-Brain Barrier
The blood-brain barrier protects the brain from harmful substances but also prevents many drugs from reaching the tumor effectively.
Tumor Microenvironment
GBM creates a highly immunosuppressive microenvironment that hinders the effectiveness of immunotherapies.
Recurrence
Even after aggressive treatment, GBM often recurs. The recurrent tumors are usually more resistant to treatment and more aggressive.
Current Standard of Care (SOC) treatment
The current SOC includes surgery, radiation and chemotherapy which can offer GBM patients an average of 12-18 months of life post diagnosis. Data from Observational Studies of GBM survivors who have taken Immune12, either alone or with current SOC treatments, has shown
– A prolonged life-span post-diagnosis, well beyond the 12-18 months.
– MRI’s showing significant tumor shrinkage, even down to zero visible tumor on MRI and PET scans.
Immune12 is a Marine sourced Complex Biologic formulated to treat GBM. Unlike current conventional drugs, which are smaller molecules, synthesized chemically, with a structure that is well-defined and simpler than large cell biologics. Due to their complexity and the sophisticated technology required for their production, biologics represent more of a challenge to both manufacture and research.
Why Participate? The Positive Aspects of our Study.
The Cancer Wellness Clinic of the Pacific’s glioblastoma participant-sponsored remote observational study offers several positive aspects for participants. Overall, our participant-sponsored remote observational study enhances the efficiency, inclusivity, and patient-centricity of GBM research.
Early Access to Cutting Edge Methods
We are now beginning to see more patient-sponsored studies taking place around the world related to Neuro based diseases such as Multiple Sclerosis and Parkinson's disease, financed either entirely or partly by their participants. Our GBM focused observational study will be the first of its kind, integrated cancer treatment and you will have early access.
Accessible, Convenient & Cost-Efficient
Our study can include participants from diverse geographic locations, including those in remote or underserved areas, making the research more inclusive. Participants can join from their homes, reducing the need for travel and making it easier for those with mobility issues or busy schedules. The CWC provides a money back guarantee for Immune12 used in this study.
Easy Recruitment & Data Collection Provide a Pathway to Market
The convenience and accessibility of a remote study supports quick recruitment with high retention rates for participants. Participants can recruit participants from their communities. Internet technologies enable remote, timely data collection, improve the accuracy and reliability of the results. The results from our study will lead to more rigorous clinical trials, government regulatory agency approvals, and thus faster consumer availability. speeding up the research process for this much needed treatment.
Empowerment in a Client-Centric Approach
These studies will focus on the participant’s experience, leading to higher satisfaction and better adherence to the study protocol. Participants will take an active role in their healthcare, which leads to increased engagement and satisfaction.